Jenoptik (JEN) Q4 2024 earnings summary

Executive summary

• Achieved robust single-digit organic revenue growth (~5%) and expanded EBITDA margin to nearly 20% of sales in 2024, despite a challenging market environment and declining order intake.

• Order intake and backlog declined year-over-year, mainly due to weakness in automotive, life science, medical technology, and non-photonic segments.

• Organizational realignment completed, now structured around four core markets, with a leaner structure for improved efficiency and customer focus.

• Completed construction of high-tech factory in Dresden, enhancing production capacity; production began in early 2025.

• Long-term growth prospects remain intact, but 2025 is viewed as a transition year with a cautious outlook due to high uncertainty.

Financial highlights

• Revenue rose 4.7% year-over-year to €1,115.8 million, with all divisions contributing; Advanced Photonic Solutions and NPC segments led growth.

• EBITDA increased 5.7% to €221.5 million, margin improved to 19.9% from 19.7%, and EPS reached €1.62, up nearly 28% year-over-year.

• EBIT rose 16.0% to €146.6 million, prior year included €12.7 million in impairments.

• Net debt reduced to €395.5 million (from €423.1 million); leverage ratio improved to 1.8x from 2.0x.

• Free cash flow before interest and tax was €102.9 million, down from €127.3 million year-over-year.

Outlook and guidance

• 2025 expected to be a transition year with revenue guidance in a ±5% corridor around 2024 levels and EBITDA margin between 18.0% and 21.0%.

• Capital expenditures projected to decline significantly in 2025, approaching maintenance levels (5–6% of sales).

• Guidance assumes stable political and economic conditions; high uncertainty persists due to geopolitical tensions, tariffs, and market volatility.

• Anticipates upturn in semiconductor equipment industry in H2 2025, assuming no further macro deterioration.